Today's Date: May 11, 2021
Susan G. Komen® Welcomes Eight New Leaders in Healthcare, Marketing and Business Operations to Board of Directors   •   MAËLYS Receives Significant Investment from Norwest    •   Miami Based Black Advertisement Agency Receives Multiple 27th Annual Communicator Awards From the Academy of Interactive and Vis   •   National Geographic Documentary Films Partners With Acclaimed Director Dawn Porter in Search of Justice and Peace 100 Years Afte   •   Survey Reveals 8 Out Of 10 Asian Americans Say They Are Discriminated Against And 77% Do Not Feel Respected In The U.S.   •   EquityPlus Completes "4% Floor" $16 Million Bond Sale To Finance Senior Citizen Affordable Housing And Community Wellness Center   •   Wells Fargo Joins OneTen Coalition to Hire, Upskill and Advance Black and African American Talent in the U.S.   •   Commvault Celebrates Inclusion of 16 Global Executives to CRN's 2021 Women of the Channel List   •   Paway Celebrates Dog Moms Throughout The Month Of May With Their "Best Dog Mom Challenge"   •   Unilever's Second Annual Day of Service Gets Sweeter at Vaccine Locations Across the Country   •   Indigenous Services Canada announces 2021 recipients of the Awards of Excellence in Nursing   •   Global War on Terrorism Memorial Foundation Gets Support From MISSION BBQ American Heroes Cup Campaign   •   AEO Inc. to Report First Quarter 2021 Results on May 26th   •   Student-Led Startup Skin Releaf Takes USD 25,000 Top Prize in Standard Chartered 2021 Women in Tech Incubator Competition   •   Accenture and Shiseido Establish Joint Venture to Accelerate Shiseido’s Digital Transformation   •   Statement - Minister of Veterans Affairs marks National Nursing Week   •   Cadence13 Partners with Globally Renowned Thought Leader, Bestselling Author, and Activist Glennon Doyle for First-Ever Podcast   •   Leading DTC Bridal Brand Azazie Launches Size Inclusive Shapewear   •   Joint statement on the 5th anniversary of Canada's full support for the United Nations Declaration on the Rights of Indigenous P   •   BlackNorth Initiative Sponsoring Lori-Ann Green-Walker, Part of the 6th Cohort of the ESG Competent Boards Certificate Program
Bookmark and Share

Solace Therapeutics Announces that Tri Valley Urology Enrolls First Patient in US Pivotal Clinical Trial, using New Office-Based

MURRIETA, Calif. , April 21 /Businesswire/ - Tri Valley Urology, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005212/en/

(Photo: Business Wire)

(Photo: Business Wire)

“I am delighted to be participating in the VESAIR Clinical Study. SUI is not life-threatening, but if left untreated, it can greatly diminish a woman’s Quality of Life. Having a non-surgical option would be a great alternative for the nearly 1 in 2 women over the age of 50, who suffer from this condition” said Benjamin T. Larson, MD, Principal Investigator for the VESAIR Clinical Study.

About Stress Urinary Incontinence and the Vesair Bladder Control System

Women with Stress Urinary Incontinence(SUI) typically experience sudden increases in bladder pressure during physical movement, for example coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethral sphincter to withstand pressure, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure force, the Vesair Bladder Control System is designed to reduce rapid increases in bladder pressure through the placement of a compressible air-filled balloon in the bladder. The balloon acts like a “shock-absorber” to slow rapid changes in pressure and reduce leakage. The uninflated balloon is placed into the bladder through the urethra and subsequently inflated. Balloon placement is performed during an in-office procedure that does not require anesthesia. When necessary, the balloon is deflated and removed in a similar in-office procedure. Most women manage their SUI with absorbent pads and are reluctant to undergo surgery for a variety of reasons. To learn more about the VESAIR Clinical Trial visit; www.vesairstudy.com.

About Solace Therapeutics, Inc.

Solace Therapeutics is an emerging women’s health company focused on a new office-based treatment for symptoms of female SUI. SUI is the most prevalent form of incontinence among women and affects an estimated 15 million adult women in the U.S. These women choose to manage their SUI by utilizing absorbent products such as protective pads versus seeking medical help. Solace is dedicated to improving the quality of life for women whose daily life is disrupted by their incontinence. Please visit www.solacetx.com to learn more about the company and review results from the first two clinical trials.


STORY TAGS: Photo/Multimedia, Medical Devices, Medical Supplies, Women, Hospitals, Clinical Trials, Other Health, Health, Consumer, General Health, California, United States, North America, Product/Service,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News